Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

SAN DIEGO, CA / ACCESSWIRE / August 28, 2024 / Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ:DXCM) securities between January 8, 2024 and July 25, 2024, both dates inclusive (the "Class Period"), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v.

DXCM INVESTOR NOTICE: DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 21, 2024.

ROSEN, A TOP RANKED LAW FIRM, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DXCM

NEW YORK, NY / ACCESSWIRE / August 28, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM LEGAL NOTICE: Lose Money on Your DexCom, Inc. Investment? Contact BFA Law about the Securities Fraud Class Action Lawsuit before the Impending Deadline

Etsy

It's time to buy on the dip. The only problem?

3 Stocks Down 20% Or More That Are Must Buys Now

Edelson Lechtzin LLP is investigating securities fraud claims on behalf of investors of Dexcom Inc. common stock (NASDAQ: DXCM) between January 8, 2024, and July 25, 2024 NEWTOWN, PA / ACCESSWIRE / August 28, 2024 / Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of investors of Dexcom Inc. common stock (NASDAQ:DXCM) between January 8, 2024, and July 25, 2024, inclusive (the "Class Period"). Investors who purchased DexCom stock may move the U.S. District Court for the Southern District of California to appoint them as lead plaintiff, no later than October 21, 2024.

DXCM INVESTOR ALERT: Edelson Lechtzin LLP Urges Dexcom, Inc. (NASDAQ: DXCM) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4th. The live presentation is scheduled to begin at approximately 11:00 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Rela.

Dexcom Announces Upcoming Conference Presentation

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM FRAUD UPDATE: A Class Action Lawsuit has been Filed Against DexCom, Inc. for Securities Fraud; Contact BFA Law Before Approaching October 21 Case Deadline (Nasdaq:DXCM)

DXCM Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / August 27, 2024 / Hagens Berman urges DexCom, Inc. (NASDAQ:DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys.

DexCom (DXCM) Accused of Misleading Investors - Hagens Berman

DXCM announces that its OTC CGM, Stelo, is now available for purchase in the United States without a prescription.

DexCom Stock May Gain on Expanded Reach After Stelo's US Launch

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).

Investors in DexCom, Inc. Should Contact The Gross Law Firm Before October 21, 2024 to Discuss Your Rights – DXCM

LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stockholders In DexCom Inc Should Contact The Schall Law Firm About An Inquiry Into The Company's Potential Securities Fraud

Intel

Moderna

Investors have been on a roller coaster ride for the past four years and the stock market may be heading into another big loop higher.

Can These 3 Nasdaq 100 Laggards Rebound in September?

NEW YORK, NY / ACCESSWIRE / August 27, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ:DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM FRAUD ALERT: DexCom, Inc. Investors that Suffered Losses are Notified to Contact BFA Law Before Upcoming October 21 Securities Fraud Deadline (NASDAQ:DXCM)

SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management.

DXCM Class Action Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the DexCom Inc. Class Action

RADNOR, PA / ACCESSWIRE / August 26, 2024 / The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. ("DexCom") (NASDAQ:DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the "Class Period") The lead plaintiff deadline is October 21, 2024. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered DexCom losses, you may CLICK HERE or go to: https://www.ktmc.com/new-cases/dexcom-inc?utm_source=PR&utm_medium=link&utm_campaign=dxcm&mktm=r You can also contact attorney Jonathan Naji, Esq.

Class Action Announcement (DXCM): A Securities Fraud Class Action Lawsuit Was Filed Against Dexcom, Inc.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. (DXCM) Investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of DexCom, Inc. (DXCM) Investors

LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DexCom Inc Is Being Investigated By The Schall Law Firm For Securities Law Infractions And Investors Are Encouraged To Reach Out

Dexcom will launch its new CGM before the end of the month. The move could help troubled Dexcom stock, which is under heavy pressure.

Will New 'Milestone' Glucose Monitor Help Dexcom Stock Bounce Back?

Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.

Dexcom launches first over-the-counter continuous glucose monitor. Here's what it's like

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTOR ALERT: DexCom, Inc. has been Sued for Securities Fraud – Investors that Suffered Losses are Urged to Contact BFA Law before October 21 (NASDAQ:DXCM)

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning DexCom business and prospects, resulting in its stock trading at inflated prices.

DXCM INVESTOR ALERT: DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Dexcom said on Monday its over-the-counter continuous glucose monitor Stelo is now available for use in the United States.

Dexcom announces launch of over-the-counter continuous glucose monitor

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription4 at Stelo.com. Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom's most accurate glucose sensing technology.5 It is specifically designed to provide the 125 million Americans6 with Typ.

Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U.S., Is Now Available

RADNOR, Pa., Aug. 25, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California against DexCom, Inc. (“DexCom”) (NASDAQ: DXCM) on behalf of investors who purchased or otherwise acquired DexCom securities between January 8, 2024 to July 25, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is October 21, 2024.

DXCM Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Dexcom, Inc. - Contact Kessler Topaz Meltzer & Check, LLP

LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for DexCom Stock (DXCM)